Lantern Pharma Inc.: 10-Q filed 2025-08-13
What Lantern Pharma Inc. reported in its quarterly report filed 2025-08-13 (fiscal Q2 2025): 32 published measures, 93 facts as tagged in accession 0001641172-25-023471.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-08-13
- Fiscal period
- fiscal Q2 2025
- Accession
- 0001641172-25-023471 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lantern Pharma Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 17,420,292 | USD | |
| At 2024-12-31 | 25,571,792 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 4,897,887 | USD | |
| At 2024-12-31 | 4,384,018 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 12,522,405 | USD | |
| At 2025-03-31 | 16,776,485 | USD | |
| At 2024-12-31 | 21,187,774 | USD | |
| At 2024-06-30 | 30,931,437 | USD | |
| At 2024-03-31 | 35,765,217 | USD | |
| At 2023-12-31 | 40,907,934 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 6,061,408 | USD | |
| At 2024-12-31 | 7,511,079 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -4,331,015 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -8,867,798 | USD | 181 |
| 2025-01-01 to 2025-03-31 | -4,536,783 | USD | 90 |
| 2024-04-01 to 2024-06-30 | -4,959,506 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -10,400,316 | USD | 182 |
| 2024-01-01 to 2024-03-31 | -5,440,810 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | -8,312,887 | USD | 181 |
| 2024-01-01 to 2024-06-30 | -8,259,161 | USD | 182 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 1,159 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 6,484 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 54,716 | USD | 182 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 6,832,489 | USD | 181 |
| 2024-01-01 to 2024-06-30 | -758,231 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | -84,893,415 | USD | |
| At 2024-12-31 | -76,025,617 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 10,784,725 | shares | 91 |
| 2025-01-01 to 2025-06-30 | 10,784,725 | shares | 181 |
| 2024-04-01 to 2024-06-30 | 10,758,805 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 10,750,801 | shares | 182 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 10,784,725 | shares | 91 |
| 2025-01-01 to 2025-06-30 | 10,784,725 | shares | 181 |
| 2024-04-01 to 2024-06-30 | 10,758,805 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 10,750,801 | shares | 182 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -0.4 | USD/shares | 91 |
| 2025-01-01 to 2025-06-30 | -0.82 | USD/shares | 181 |
| 2024-04-01 to 2024-06-30 | -0.46 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -0.97 | USD/shares | 182 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -0.4 | USD/shares | 91 |
| 2025-01-01 to 2025-06-30 | -0.82 | USD/shares | 181 |
| 2024-04-01 to 2024-06-30 | -0.46 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -0.97 | USD/shares | 182 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 39,524 | USD | |
| At 2024-12-31 | 47,440 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 160,626 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 308,376 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 134,171 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 268,228 | USD | 182 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -4,651,900 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -9,425,932 | USD | 181 |
| 2024-04-01 to 2024-06-30 | -5,408,461 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -11,140,462 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 17,200,790 | USD | |
| At 2024-12-31 | 25,247,629 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 4,884,363 | USD | |
| At 2024-12-31 | 4,331,175 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 4,651,900 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 9,425,932 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 5,408,461 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 11,140,462 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 3,068,379 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 6,332,334 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 3,888,737 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 8,139,523 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 10,784,725 | shares | |
| At 2024-12-31 | 10,784,725 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 97,366,699 | USD | |
| At 2024-12-31 | 97,058,323 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 48,043 | USD | |
| At 2024-12-31 | 153,990 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 143,240 | USD | |
| At 2024-12-31 | 239,985 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 145,039 | USD | |
| At 2024-12-31 | 243,657 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 36,738 | USD | |
| At 2024-12-31 | 36,738 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 1,299,016 | USD | |
| At 2024-12-31 | 1,234,566 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -4,414,706 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -8,973,745 | USD | 181 |
| 2024-04-01 to 2024-06-30 | -4,967,951 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -10,299,441 | USD | 182 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 1,583,521 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 3,093,598 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 1,519,724 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 3,000,939 | USD | 182 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 206,140 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 293,599 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 260,295 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 350,536 | USD | 182 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 108,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 91,000 | USD | 182 |
Inspect the source
- Entity
- Lantern Pharma Inc. / CIK 0001763950
- Captured
- 2026-09-21T17:26:28.194Z
- SEC response SHA-256
de4123361405efcd0291343ed94db7c24d43e6c36dbcd4d45ba588f463c7f9d1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001763950.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))